Uy Ear
Stock Analyst at Mizuho
(3.08)
# 1,093
Out of 4,814 analysts
60
Total ratings
38.24%
Success rate
14.57%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TECX Tectonic Therapeutic | Initiates: Outperform | $51 | $17.02 | +199.65% | 1 | Apr 21, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $20 → $21 | $13.01 | +61.41% | 14 | Feb 26, 2025 | |
| QURE uniQure | Maintains: Neutral | $7 → $20 | $13.00 | +53.85% | 4 | Dec 19, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $0.29 | +245.07% | 1 | Dec 5, 2024 | |
| ALKS Alkermes | Maintains: Outperform | $35 → $40 | $27.20 | +47.06% | 5 | Nov 13, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $18 → $16 | $7.43 | +115.34% | 2 | Jul 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $10.40 | +284.62% | 1 | May 24, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $145 → $179 | $53.79 | +232.78% | 5 | May 17, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $25 → $21 | $14.73 | +42.57% | 10 | May 9, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $10.80 | +113.06% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $116 → $140 | $100.10 | +39.86% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $157.47 | -74.60% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.11 | +800.90% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $0.65 | +359.28% | 2 | Mar 1, 2023 |
Tectonic Therapeutic
Apr 21, 2025
Initiates: Outperform
Price Target: $51
Current: $17.02
Upside: +199.65%
Arcutis Biotherapeutics
Feb 26, 2025
Maintains: Outperform
Price Target: $20 → $21
Current: $13.01
Upside: +61.41%
uniQure
Dec 19, 2024
Maintains: Neutral
Price Target: $7 → $20
Current: $13.00
Upside: +53.85%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $0.29
Upside: +245.07%
Alkermes
Nov 13, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $27.20
Upside: +47.06%
Sage Therapeutics
Jul 19, 2024
Maintains: Neutral
Price Target: $18 → $16
Current: $7.43
Upside: +115.34%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $10.40
Upside: +284.62%
Sarepta Therapeutics
May 17, 2024
Maintains: Buy
Price Target: $145 → $179
Current: $53.79
Upside: +232.78%
ACADIA Pharmaceuticals
May 9, 2024
Maintains: Neutral
Price Target: $25 → $21
Current: $14.73
Upside: +42.57%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $10.80
Upside: +113.06%
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $100.10
Upside: +39.86%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $157.47
Upside: -74.60%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $1.11
Upside: +800.90%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $0.65
Upside: +359.28%